Shares of Auris Medical Holding AG (NASDAQ:EARS) traded up 0% during trading on Tuesday . The stock traded as high as $0.30 and last traded at $0.29. 623,700 shares were traded during mid-day trading, a decline of 36% from the average session volume of 981,479 shares. The stock had previously closed at $0.29.

Separately, ValuEngine raised Auris Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04. The stock has a market cap of $13.58, a P/E ratio of -0.48 and a beta of 0.11.

Auris Medical (NASDAQ:EARS) last announced its quarterly earnings results on Tuesday, November 28th. The biotechnology company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.

An institutional investor recently bought a new position in Auris Medical stock. Virtu KCG Holdings LLC purchased a new stake in Auris Medical Holding AG (NASDAQ:EARS) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned approximately 0.32% of Auris Medical at the end of the most recent reporting period. 18.76% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://theolympiareport.com/2018/02/13/auris-medical-ears-trading-0-higher.html.

Auris Medical Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.